Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study
Close
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
282 0
SM ISO690:2012
PENN-NICHOLSON, Adam, GEORGHIOU, Sophia B., CIOBANU, Nelly, KAZI, Mubin I., BHALLA, Manpreet, DAVID, Anura, CONRADIE, Francesca M., RUHWALD, Morten, KRUDU, V., RODRIGUES, Camilla S., MYNEEDU, Vithal Prasad, SCOTT, Lesley, DENKINGER, Claudia M., SCHUMACHER, Samuel G.. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. In: The Lancet Infectious Diseases, 2022, vol. 22, pp. 242-249. ISSN 1473-3099. DOI: https://doi.org/10.1016/S1473-3099(21)00452-7
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
The Lancet Infectious Diseases
Volumul 22 / 2022 / ISSN 1473-3099 /ISSNe 1474-4457

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

DOI: https://doi.org/10.1016/S1473-3099(21)00452-7

Pag. 242-249

Penn-Nicholson Adam1, Georghiou Sophia B.1, Ciobanu Nelly2, Kazi Mubin I.3, Bhalla Manpreet4, David Anura5, Conradie Francesca M.5, Ruhwald Morten1, Krudu V.2, Rodrigues Camilla S.6, Myneedu Vithal Prasad4, Scott Lesley5, Denkinger Claudia M.71, Schumacher Samuel G.1
 
1 FIND, Geneva,
2 Institute of Phtysiopneumology „Chiril Draganiuc”,
3 Hinduja Hospital and Research Centre, Mumbai,
4 National Institute of TB and Respiratory Diseases, New Delhi,
5 University of Witwatersrand,
6 Hinduja National Hospital, Mumbai,
7 University Hospital Heidelberg
 
Disponibil în IBN: 6 februarie 2022


Rezumat

Background: The WHO End TB Strategy requires drug susceptibility testing and treatment of all people with tuberculosis, but second-line diagnostic testing with line-probe assays needs to be done in experienced laboratories with advanced infrastructure. Fewer than half of people with drug-resistant tuberculosis receive appropriate treatment. We assessed the diagnostic accuracy of the rapid Xpert MTB/XDR automated molecular assay (Cepheid, Sunnyvale, CA, USA) to overcome these limitations. Methods: We did a prospective study involving individuals presenting with pulmonary tuberculosis symptoms and at least one risk factor for drug resistance in four sites in India (New Delhi and Mumbai), Moldova, and South Africa between July 31, 2019, and March 21, 2020. The Xpert MTB/XDR assay was used as a reflex test to detect resistance to isoniazid, fluoroquinolones, ethionamide, amikacin, kanamycin, and capreomycin in adults with positive results for Mycobacterium tuberculosis complex on Xpert MTB/RIF or Ultra (Cepheid). Diagnostic performance was assessed against a composite reference standard of phenotypic drug-susceptibility testing and whole-genome sequencing. This study is registered with ClinicalTrials.gov, number NCT03728725. Findings: Of 710 participants, 611 (86%) had results from both Xpert MTB/XDR and the reference standard for any drug and were included in analysis. Sensitivity for Xpert MTB/XDR detection of resistance was 94% (460 of 488, 95% CI 92–96) for isoniazid, 94% (222 of 235, 90–96%) for fluoroquinolones, 54% (178 of 328, 50–61) for ethionamide, 73% (60 of 82, 62–81) for amikacin, 86% (181 of 210, 81–91) for kanamycin, and 61% (53 of 87, 49–70) for capreomycin. Specificity was 98–100% for all drugs. Performance was equivalent to that of line-probe assays. The non-determinate rate of Xpert MTB/XDR (ie, invalid M tuberculosis complex detection) was 2·96%. Interpretation: The Xpert MTB/XDR assay showed high diagnostic accuracy and met WHO's minimum target product profile criteria for a next-generation drug susceptibility test. The assay has the potential to diagnose drug-resistant tuberculosis rapidly and accurately and enable optimum treatment. Funding: German Federal Ministry of Education and Research through KfW, Dutch Ministry of Foreign Affairs, and Australian Department of Foreign Affairs and Trade.